Masimo Corporation (MASI)
Here's Why Masimo (MASI) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Masimo's Board Backs Danaher's $9.9B Cash Acquisition Proposal
MASI will be acquired by Danaher for $9.9B in cash, sending shares soaring as the medtech firm prepares to join DHR's Diagnostics segment.
What's Happening With Masimo Stock?
Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only partially offsets a period of long-term stagnation.
Strength Seen in Masimo (MASI): Can Its 34.2% Jump Turn into More Strength?
Masimo (MASI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Shares of Masimo, Danaher Moving on Acquisition Buzz
Medical technology stock Masimo Corp (NASDAQ:MASI) is soaring today, last seen up 34.3% to trade at $174.78, after reports that the company is nearing an agreement to be acquired by Danaher Corp (NYSE:DHR) in an all-cash deal worth roughly $10 billion.
5 Things to Know Before the Stock Market Opens
Stock futures are pointing lower to open the holiday-shortened trading week after tech-related worries sent U.S. equities sharply lower last week; shares of Norwegian Cruise Line Holdings are gaining as activist investor Elliott Investment Management has reportedly built a stake in the cruise operator; Warner Bros. Discover, which has a deal to be acquired by Netflix, will reopen talks with Paramount Skydance; shares of Masimo are surging following news that the medical device maker is being acquired by Danaher in a $10 billion deal; and cybersecurity software maker Palo Alto Networks is scheduled to report earnings after the closing bell.
Here's Why You Should Add Masimo Stock to Your Portfolio Now
MASI targets 7%-10% revenue growth through 2028, sharp margin expansion and rising cash flow as intelligent monitoring and partnerships gain traction.
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wall Street Analysts Think Masimo (MASI) Could Surge 31.06%: Read This Before Placing a Bet
The consensus price target hints at a 31.1% upside potential for Masimo (MASI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Masimo Stock Declines Despite Solid Preliminary Q4 Revenues
MASI posts strong fourth-quarter and full-year 2025 preliminary results with revenue and EPS above estimates, driven by core healthcare momentum.
Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Masimo Corporation (MASI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
